Characterisation of liver-specific distribution of a novel 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonist, SKL-13784: comparison with GC-1

References

• Baxter JD, Webb P. (2009). Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 8:308–20
   PubMed Web of Science ®Google Scholar
• Berkenstam A, Kristensen J, Mellström K, et al. (2008). The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 105:663–7
   PubMed Web of Science ®Google Scholar
• Chiellini G, Nguyen NH, Yoshihara HA, Scanlan TS. (2000). Improved synthesis of the iodine-free thyromimetic GC-1. Bioorg Med Chem Lett 10:2607–11
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• Erion MD, van Poelje PD, Mackenna DA, et al. (2005). Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther 312:554–60
   PubMed Web of Science ®Google Scholar
• Erion MD, Cable EE, Ito BR, et al. (2007). Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 104:15490–5
   PubMed Web of Science ®Google Scholar
• Flamant F, Samarut J. (2003). Thyroid hormone receptors: lessons from knockout and knock-in mutant mice. Trends Endocrinol Metab 14:85–90
   PubMed Web of Science ®Google Scholar
• Forrest D, Vennström B. (2000). Functions of thyroid hormone receptors in mice. Thyroid 10:41–52
   PubMed Web of Science ®Google Scholar
• Fujitaki JM, Cable EE, Ito BR, et al. (2008). Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist. Drug Metab Dispos 36:2393–403
   PubMed Web of Science ®Google Scholar
• Fukuyama T, Yamaoka K, Ohata Y, Nakagawa T. (1994). A new analysis method for disposition kinetics of enterohepatic circulation of diclofenac in rats. Drug Metab Dispos 22:479–85
   PubMed Web of Science ®Google Scholar
• Grover GJ, Mellström K, Ye L, et al. (2003). Selective thyroid hormone receptor-β activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 100:10067–72
   PubMed Web of Science ®Google Scholar
• Grover GJ, Egan DM, Sleph PG, et al. (2004). Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3′-triiodo-l-thyronine. Endocrinology 145:1656–61
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Meier PJ. (2004). Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653–65
   PubMed Web of Science ®Google Scholar
• Houston JB, Carlile DJ. (1997). Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29:891–922
   PubMed Web of Science ®Google Scholar
• Imaoka T, Mikkaichi T, Abe K, et al. (2013). Integrated approach of in vivo and in vitro evaluation of the involvement of hepatic uptake organic anion transporters in the drug disposition in rats using rifampicin as an inhibitor. Drug Metab Dispos 41:1442–9
   PubMed Web of Science ®Google Scholar
• Kramer W, Wess G, Schubert G, et al. (1992). Liver-specific drug targeting by coupling to bile acids. J Biol Chem 267:18598–604
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Sugiyama Y. (2002). Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release 78:43–54
   PubMed Web of Science ®Google Scholar
• Lau YY, Okochi H, Huang Y, Benet LZ. (2006). Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316:762–71
   PubMed Web of Science ®Google Scholar
• Lew W, Chen X, Kim CU. (2000). Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr Med Chem 7:663–72
   PubMed Web of Science ®Google Scholar
• Matsushima S, Maeda K, Kondo C, et al. (2005). Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 314:1059–67
   PubMed Web of Science ®Google Scholar
• Meijer DK, Molema G. (1995). Targeting of drugs to the liver. Semin Liver Dis 15:202–56
   PubMed Web of Science ®Google Scholar
• Müller M, Jansen PL. (1997). Molecular aspects of hepatobiliary transport. Am J Physiol 272:G1285–303
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58
   PubMed Web of Science ®Google Scholar
• O'Shea PJ, Williams GR. (2002). Insight into the physiological actions of thyroid hormone receptors from genetically modified mice. J Endocrinol 175:553–70
   PubMed Web of Science ®Google Scholar
• Soars MG, Grime K, Sproston JL, et al. (2007). Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859–65
   PubMed Web of Science ®Google Scholar
• Takahashi N, Maeda K, Asano Y, Watanabe N. (2014a). Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists. Bioorg Med Chem 22:488–98
   PubMed Web of Science ®Google Scholar
• Takahashi N, Asano Y, Maeda K, Watanabe N. (2014b). In vivo evaluation of 1-benzyl-4-aminoindole-based thyroid hormone receptor β agonists: importance of liver selectivity in drug discovery. Biol Pharm Bull 37:1103–8
   PubMed Web of Science ®Google Scholar
• Tancevski I, Eller P, Patsch JR, Ritsch A. (2009). The resurgence of thyromimetics as lipid-modifying agents. Curr Opin Investig Drugs 10:912–18
   PubMed Web of Science ®Google Scholar
• Tian X, Li J, Zamek-Gliszczynski MJ, et al. (2007). Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrob Agents Chemother 51:3230–4
   PubMed Web of Science ®Google Scholar
• Trost SU, Swanson E, Gloss B, et al. (2000). The thyroid hormone receptor-β-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 141:3057–64
   PubMed Web of Science ®Google Scholar
• Tu M, Mathiowetz AM, Pfefferkorn JA, et al. (2013). Medicinal chemistry design principles for liver targeting through OATP transporters. Curr Top Med Chem 13:857–66
   PubMed Web of Science ®Google Scholar
• Varma MV, Chang G, Lai Y, et al. (2012). Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion. Drug Metab Dispos 40:1527–37
   PubMed Web of Science ®Google Scholar
• Wikström L, Johansson C, Saltó C, et al. (1998). Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor α1. EMBO J 17:455–61
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Suzuki H, Sugiyama Y. (1996). Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13:497–513
   PubMed Web of Science ®Google Scholar
• Yen PM. (2001). Physiological and molecular basis of thyroid hormone action. Physiol Rev 81:1097–142
   PubMed Web of Science ®Google Scholar
• Ye ZW, Augustijns P, Annaert P. (2008). Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors. Drug Metab Dispos 36:1315–21
   PubMed Web of Science ®Google Scholar